MEDINDIA
English
हिन्दी
Español
français
中文
Email
17-alpha-Hydroxyprogesterone
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Hydroxyprogesterone caproate.
Abacavir
The serum concentration of Abacavir can be decreased when it is combined with Linagliptin.
Acetohexamide
Linagliptin may increase the hypoglycemic activities of Acetohexamide.
Aldosterone
The serum concentration of Linagliptin can be decreased when it is combined with Aldosterone.
Alfuzosin
The serum concentration of Alfuzosin can be increased when it is combined with Linagliptin.
Alprazolam
The serum concentration of Alprazolam can be increased when it is combined with Linagliptin.
AMBROXOL ACEFYLLINATE
The serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Linagliptin.
Ambroxol-Theophylline-7-Acetate
The serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Linagliptin.
Amineptin
The serum concentration of Amineptine can be increased when it is combined with Linagliptin.
Aminophylline
The serum concentration of Aminophylline can be decreased when it is combined with Linagliptin.
Amiodarone
The serum concentration of Linagliptin can be decreased when it is combined with Amiodarone.
Amitriptyline
The serum concentration of Amitriptyline can be increased when it is combined with Linagliptin.
Amoxapine
The serum concentration of Amoxapine can be increased when it is combined with Linagliptin.
Amprenavir
The serum concentration of Linagliptin can be decreased when it is combined with Amprenavir.
Anhydrous Tacrolimus
The serum concentration of Linagliptin can be decreased when it is combined with Tacrolimus.
Apalutamide
The serum concentration of Linagliptin can be decreased when it is combined with Apalutamide.
Aripiprazole
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Aripiprazole.
Arsenic Trioxide
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Arsenic trioxide.
Articaine
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Articaine.
Asenapine
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Asenapine.
Atazanavir
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Atazanavir.
Atorvastatin
The risk or severity of adverse effects can be increased when Linagliptin is combined with Atorvastatin.
Benazepril
The risk or severity of adverse effects can be increased when Linagliptin is combined with Benazepril.
Bendroflumethiazide
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Bendroflumethiazide.
Betamethasone
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Betamethasone.
Boceprevir
The serum concentration of Linagliptin can be decreased when it is combined with Boceprevir.
Bosutinib
The serum concentration of Bosutinib can be increased when it is combined with Linagliptin.
Bosutinib monohydrate
The serum concentration of Bosutinib can be increased when it is combined with Linagliptin.
Brexpiprazole
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Brexpiprazole.
Bromocriptine
The risk or severity of adverse effects can be increased when Bromocriptine is combined with Linagliptin.
Bumetanide
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Bumetanide.
Buserelin
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Buserelin.
Cabergoline
The serum concentration of Cabergoline can be increased when it is combined with Linagliptin.
Captopril
The risk or severity of adverse effects can be increased when Linagliptin is combined with Captopril.
Carbamazepine
The metabolism of Linagliptin can be increased when combined with Carbamazepine.
Ceritinib
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Ceritinib.
Cerivastatin
The serum concentration of Cerivastatin can be increased when it is combined with Linagliptin.
Chlorothiazide
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Chlorothiazide.
Chlorotrianisene
The serum concentration of Chlorotrianisene can be decreased when it is combined with Linagliptin.
Chlorpropamide
Linagliptin may increase the hypoglycemic activities of Chlorpropamide.
Chlorthalidone
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Chlorthalidone.
Cholic Acid
The serum concentration of Linagliptin can be decreased when it is combined with Cholic Acid.
Cilazapril
The risk or severity of adverse effects can be increased when Linagliptin is combined with Cilazapril.
Cimetidine
The serum concentration of Linagliptin can be decreased when it is combined with Cimetidine.
Clarithromycin
The therapeutic efficacy of Clarithromycin can be decreased when used in combination with Linagliptin.
Clomipramine
The serum concentration of Clomipramine can be increased when it is combined with Linagliptin.
Clotrimazole
The serum concentration of Linagliptin can be decreased when it is combined with Clotrimazole.
Clozapine
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Clozapine.
coenzyme Q10
The therapeutic efficacy of Linagliptin can be increased when used in combination with Ubidecarenone.
Corticotropin
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Corticotropin.
Cortisone Acetate
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Cortisone acetate.
Cyclobenzaprine
The serum concentration of Cyclobenzaprine can be increased when it is combined with Linagliptin.
Cyclopenthiazide
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Cyclopenthiazide.
Cyclophosphamide
The risk or severity of adverse effects can be increased when Linagliptin is combined with Cyclophosphamide.
Cyclophosphamide Anhydrous
The risk or severity of adverse effects can be increased when Linagliptin is combined with Cyclophosphamide.
Cyclosporine
The serum concentration of Linagliptin can be decreased when it is combined with Cyclosporine.
Cyproterone Acetate
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Cyproterone acetate.
Dabrafenib
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Dabrafenib.
Danazol
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Danazol.
Darunavir
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Darunavir.
Daunorubicin
The serum concentration of Linagliptin can be decreased when it is combined with Daunorubicin.
Delavirdine
The serum concentration of Delavirdine can be decreased when it is combined with Linagliptin.
Desipramine
The serum concentration of Desipramine can be increased when it is combined with Linagliptin.
Desogestrel
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Desogestrel.
Dexamethasone
The serum concentration of Linagliptin can be decreased when it is combined with Dexamethasone.
Diazoxide
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Diazoxide.
Dienestrol
The serum concentration of Dienestrol can be decreased when it is combined with Linagliptin.
Dienogest
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Dienogest.
Diethylstilbestrol
The serum concentration of Diethylstilbestrol can be decreased when it is combined with Linagliptin.
Digoxin
The serum concentration of Linagliptin can be decreased when it is combined with Digoxin.
Dihydroergotamine
The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Linagliptin.
Diltiazem
The metabolism of Diltiazem can be decreased when combined with Linagliptin.
Disopyramide
Linagliptin may increase the hypoglycemic activities of Disopyramide.
Dothiepin
The serum concentration of Dosulepin can be increased when it is combined with Linagliptin.
Doxepin
The serum concentration of Doxepin can be increased when it is combined with Linagliptin.
Doxorubicin
The serum concentration of Linagliptin can be decreased when it is combined with Doxorubicin.
Doxorubicin Hydrochloride
The serum concentration of Linagliptin can be decreased when it is combined with Doxorubicin.
Drospirenone
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Drospirenone.
Dyphylline
The serum concentration of Dyphylline can be decreased when it is combined with Linagliptin.
Enalapril
The risk or severity of adverse effects can be increased when Linagliptin is combined with Enalapril.
Enalaprilat
The risk or severity of adverse effects can be increased when Linagliptin is combined with Enalaprilat.
Enalaprilat Anhydrous
The risk or severity of adverse effects can be increased when Linagliptin is combined with Enalaprilat.
Enfuvirtide
The serum concentration of Enfuvirtide can be increased when it is combined with Linagliptin.
Enzalutamide
The serum concentration of Linagliptin can be decreased when it is combined with Enzalutamide.
Epinephrine
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Epinephrine.
ergoloid mesylates, USP
The serum concentration of Ergoloid mesylate can be increased when it is combined with Linagliptin.
Ergonovine
The risk or severity of adverse effects can be increased when Ergonovine is combined with Linagliptin.
Ergotamine
The risk or severity of adverse effects can be increased when Ergotamine is combined with Linagliptin.
Estradiol
The serum concentration of Estradiol can be decreased when it is combined with Linagliptin.
Estramustine
The serum concentration of Estramustine can be decreased when it is combined with Linagliptin.
Estriol
The serum concentration of Linagliptin can be decreased when it is combined with Estriol.
Estrogens, Conjugated (USP)
The serum concentration of Conjugated estrogens can be decreased when it is combined with Linagliptin.
Estrogens, Esterified (USP)
The serum concentration of Estrogens, esterified can be decreased when it is combined with Linagliptin.
Estrone
The serum concentration of Linagliptin can be decreased when it is combined with Estrone.
Ethacrynate
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Etacrynic acid.
Ethacrynic Acid
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Etacrynic acid.
Ethinyl Estradiol
The serum concentration of Ethinyl Estradiol can be decreased when it is combined with Linagliptin.
Ethynodiol Diacetate
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Ethynodiol diacetate.
Etonogestrel
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Etonogestrel.
Etravirine
The serum concentration of Etravirine can be decreased when it is combined with Linagliptin.
Everolimus
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Everolimus.
Fludrocortisone
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Fludrocortisone.
Fluvastatin
The serum concentration of Fluvastatin can be increased when it is combined with Linagliptin.
Fosamprenavir
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Fosamprenavir.
Fosinopril
The risk or severity of adverse effects can be increased when Linagliptin is combined with Fosinopril.
Fosphenytoin
The serum concentration of Linagliptin can be decreased when it is combined with Fosphenytoin.
Furosemide
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Furosemide.
Garlic Allergenic Extract
The serum concentration of Linagliptin can be decreased when it is combined with Garlic.
Glibornuride
Linagliptin may increase the hypoglycemic activities of Glibornuride.
Gliclazide
Linagliptin may increase the hypoglycemic activities of Gliclazide.
Glimepiride
Linagliptin may increase the hypoglycemic activities of Glimepiride.
Glipizide
Linagliptin may increase the hypoglycemic activities of Glipizide.
Gliquidone
Linagliptin may increase the hypoglycemic activities of Gliquidone.
Glyburide
Linagliptin may increase the hypoglycemic activities of Glyburide.
Goserelin
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Goserelin.
Histrelin
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Histrelin.
Hydrochlorothiazide
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Hydrochlorothiazide.
Hydrocortisone
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Hydrocortisone.
Hydroflumethiazide
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Hydroflumethiazide.
hydroxyprogesterone caproate (USP)
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Hydroxyprogesterone caproate.
Hypoxis hemerocallidea root extract
The metabolism of Linagliptin can be increased when combined with St. John's Wort.
Ibrutinib
The serum concentration of Ibrutinib can be increased when it is combined with Linagliptin.
Iloperidone
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Iloperidone.
Imidapril
The risk or severity of adverse effects can be increased when Linagliptin is combined with Imidapril.
Imipramine
The serum concentration of Imipramine can be increased when it is combined with Linagliptin.
Indapamide
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Indapamide.
Indinavir
The serum concentration of Linagliptin can be decreased when it is combined with Indinavir.
INDINAVIR ANHYDROUS
The serum concentration of Linagliptin can be decreased when it is combined with Indinavir.
Insulin Detemir
Linagliptin may increase the hypoglycemic activities of Insulin Detemir.
Insulin Glargine
Linagliptin may increase the hypoglycemic activities of Insulin Glargine.
insulin human, rDNA origin
Linagliptin may increase the hypoglycemic activities of Insulin Human.
Insulin Lispro
Linagliptin may increase the hypoglycemic activities of Insulin Lispro.
Insulin, Aspart Protamine, Human
Linagliptin may increase the hypoglycemic activities of Insulin Aspart.
Insulin, Aspart, Human
Linagliptin may increase the hypoglycemic activities of Insulin Aspart.
Insulin, Glulisine, Human
Linagliptin may increase the hypoglycemic activities of Insulin Glulisine.
Insulin, Pork
Linagliptin may increase the hypoglycemic activities of Insulin Pork.
Insulin, Protamine Lispro, Human
Linagliptin may increase the hypoglycemic activities of Insulin Lispro.
Insulin, Regular, Pork
Linagliptin may increase the hypoglycemic activities of Insulin Pork.
Isavuconazole
The serum concentration of Linagliptin can be increased when it is combined with Isavuconazole.
Lanreotide
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Lanreotide.
Leuprolide
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Leuprolide.
Levonorgestrel
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Levonorgestrel.
Levothyroxine
The serum concentration of Linagliptin can be decreased when it is combined with Levothyroxine.
Liothyronine
The serum concentration of Linagliptin can be decreased when it is combined with Liothyronine.
Lisinopril
The risk or severity of adverse effects can be increased when Linagliptin is combined with Lisinopril.
Lisinopril Anhydrous
The risk or severity of adverse effects can be increased when Linagliptin is combined with Lisinopril.
Lisuride
The risk or severity of adverse effects can be increased when Lisuride is combined with Linagliptin.
Lopinavir
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Lopinavir.
Lovastatin
The serum concentration of Lovastatin can be increased when it is combined with Linagliptin.
Lumacaftor
The serum concentration of Linagliptin can be decreased when it is combined with Lumacaftor.
Lurasidone
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Lurasidone.
Mecasermin
Linagliptin may increase the hypoglycemic activities of Mecasermin.
Mecasermin Rinfabate
Linagliptin may increase the hypoglycemic activities of Mecasermin.
Medrogestone
The serum concentration of Linagliptin can be decreased when it is combined with Medrogestone.
Medroxyprogesterone Acetate
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Medroxyprogesterone acetate.
Megestrol Acetate
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Megestrol acetate.
Meperidine
The risk or severity of adverse effects can be increased when Linagliptin is combined with Pethidine.
Mestranol
The serum concentration of Mestranol can be decreased when it is combined with Linagliptin.
Metergoline
The risk or severity of adverse effects can be increased when Metergoline is combined with Linagliptin.
Methotrimeprazine
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Methotrimeprazine.
Methyclothiazide
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Methyclothiazide.
Methylergonovine
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Linagliptin.
Methylprednisolone
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Methylprednisolone.
Methysergide
The risk or severity of adverse effects can be increased when Methysergide is combined with Linagliptin.
Metolazone
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Metolazone.
Midazolam
The serum concentration of Midazolam can be increased when it is combined with Linagliptin.
Mifepristone
The serum concentration of Linagliptin can be decreased when it is combined with Mifepristone.
Mirtazapine
The serum concentration of Mirtazapine can be increased when it is combined with Linagliptin.
Mitotane
The serum concentration of Linagliptin can be decreased when it is combined with Mitotane.
Mitoxantrone
The serum concentration of Linagliptin can be decreased when it is combined with Mitoxantrone.
Moexipril
The risk or severity of adverse effects can be increased when Linagliptin is combined with Moexipril.
Nateglinide
Linagliptin may increase the hypoglycemic activities of Nateglinide.
Nefazodone
The serum concentration of Nefazodone can be increased when it is combined with Linagliptin.
Nelfinavir
The serum concentration of Linagliptin can be decreased when it is combined with Nelfinavir.
Nevirapine
The serum concentration of Linagliptin can be decreased when it is combined with Nevirapine.
Niacin
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Niacin.
Nicergoline
The risk or severity of adverse effects can be increased when Nicergoline is combined with Linagliptin.
Nifedipine
The serum concentration of Linagliptin can be decreased when it is combined with Nifedipine.
Nilotinib
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Nilotinib.
Norethindrone
The serum concentration of Linagliptin can be decreased when it is combined with Norethisterone.
Norgestimate
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Norgestimate.
Nortriptyline
The serum concentration of Nortriptyline can be increased when it is combined with Linagliptin.
Octreotide
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Octreotide.
Olanzapine
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Olanzapine.
Opipramol
The serum concentration of Opipramol can be increased when it is combined with Linagliptin.
Paliperidone
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Paliperidone.
Pasireotide
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Pasireotide.
Pentamidine
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Pentamidine.
Pentobarbital
The serum concentration of Linagliptin can be decreased when it is combined with Pentobarbital.
Pergolide
The risk or severity of adverse effects can be increased when Pergolide is combined with Linagliptin.
Perindopril
The risk or severity of adverse effects can be increased when Linagliptin is combined with Perindopril.
Phenobarbital
The serum concentration of Linagliptin can be decreased when it is combined with Phenobarbital.
Phenytoin
The serum concentration of Linagliptin can be decreased when it is combined with Phenytoin.
Piperazine
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Piperazine.
Pipothiazine
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Pipotiazine.
Pitavastatin
The serum concentration of Pitavastatin can be increased when it is combined with Linagliptin.
Polythiazide
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Polythiazide.
Pravastatin
The serum concentration of Pravastatin can be increased when it is combined with Linagliptin.
Prednisolone
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Prednisolone.
Prednisone
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Prednisone.
Pregabalin
The risk or severity of heart failure can be increased when Pregabalin is combined with Linagliptin.
Primidone
The serum concentration of Linagliptin can be decreased when it is combined with Primidone.
Progesterone
The serum concentration of Linagliptin can be decreased when it is combined with Progesterone.
Protriptyline
The serum concentration of Protriptyline can be increased when it is combined with Linagliptin.
Quetiapine
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Quetiapine.
Quetiapine fumarate
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Quetiapine.
Quinapril
The risk or severity of adverse effects can be increased when Linagliptin is combined with Quinapril.
Quinethazone
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Quinethazone.
Quinine
Linagliptin may increase the hypoglycemic activities of Quinine.
Ramipril
The risk or severity of adverse effects can be increased when Linagliptin is combined with Ramipril.
Ranolazine
The serum concentration of Linagliptin can be increased when it is combined with Ranolazine.
Regular Insulin, Human
Linagliptin may increase the hypoglycemic activities of Insulin Human.
Repaglinide
Linagliptin may increase the hypoglycemic activities of Repaglinide.
Rescinnamine
The risk or severity of adverse effects can be increased when Linagliptin is combined with Rescinnamine.
Reserpine
The serum concentration of Linagliptin can be decreased when it is combined with Reserpine.
Rifabutin
The serum concentration of Linagliptin can be decreased when it is combined with Rifabutin.
Rifampin
The serum concentration of Linagliptin can be decreased when it is combined with Rifampicin.
Rifapentine
The serum concentration of Linagliptin can be decreased when it is combined with Rifapentine.
Rilpivirine
The serum concentration of Rilpivirine can be increased when it is combined with Linagliptin.
Riociguat
The serum concentration of Riociguat can be increased when it is combined with Linagliptin.
Risperidone
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Risperidone.
Ritonavir
The serum concentration of Linagliptin can be increased when it is combined with Ritonavir.
Rosuvastatin
The serum concentration of Rosuvastatin can be increased when it is combined with Linagliptin.
Saquinavir
The serum concentration of Linagliptin can be decreased when it is combined with Saquinavir.
Saquinavir Mesylate
The serum concentration of Linagliptin can be decreased when it is combined with Saquinavir.
Sildenafil
The serum concentration of Sildenafil can be increased when it is combined with Linagliptin.
Simvastatin
The serum concentration of Simvastatin can be increased when it is combined with Linagliptin.
Sirolimus
The serum concentration of Linagliptin can be decreased when it is combined with Sirolimus.
Spirapril
The risk or severity of adverse effects can be increased when Linagliptin is combined with Spirapril.
ST. JOHN'S WORT EXTRACT
The metabolism of Linagliptin can be increased when combined with St. John's Wort.
Streptozocin
The serum concentration of Linagliptin can be decreased when it is combined with Streptozocin.
Sulfadiazine
Linagliptin may increase the hypoglycemic activities of Sulfadiazine.
Sulfamethoxazole
Linagliptin may increase the hypoglycemic activities of Sulfamethoxazole.
Sulfisoxazole
Linagliptin may increase the hypoglycemic activities of Sulfisoxazole.
Sunitinib
Linagliptin may increase the hypoglycemic activities of Sunitinib.
synthetic conjugated estrogens, A
The serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Linagliptin.
Tacrolimus
The serum concentration of Linagliptin can be decreased when it is combined with Tacrolimus.
Tamoxifen
The serum concentration of Linagliptin can be decreased when it is combined with Tamoxifen.
Temsirolimus
The risk or severity of adverse effects can be increased when Linagliptin is combined with Temsirolimus.
Theophylline
The serum concentration of Theophylline can be decreased when it is combined with Linagliptin.
Theophylline anhydrous
The serum concentration of Theophylline can be decreased when it is combined with Linagliptin.
Thioctic Acid
Lipoic Acid may increase the hypoglycemic activities of Linagliptin.
Tianeptine
The serum concentration of Tianeptine can be increased when it is combined with Linagliptin.
Tipranavir
The serum concentration of Linagliptin can be decreased when it is combined with Tipranavir.
Tolazamide
Linagliptin may increase the hypoglycemic activities of Tolazamide.
Tolbutamide
Linagliptin may increase the hypoglycemic activities of Tolbutamide.
Tolvaptan
The serum concentration of Tolvaptan can be increased when it is combined with Linagliptin.
Torsemide
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Torasemide.
Trandolapril
The risk or severity of adverse effects can be increased when Linagliptin is combined with Trandolapril.
Trazodone
The serum concentration of Linagliptin can be decreased when it is combined with Trazodone.
Triamcinolone
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Triamcinolone.
Triazolam
The serum concentration of Triazolam can be increased when it is combined with Linagliptin.
Trichlormethiazide
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Trichlormethiazide.
Trimethoprim
The serum concentration of Linagliptin can be decreased when it is combined with Trimethoprim.
Trimipramine
The serum concentration of Trimipramine can be increased when it is combined with Linagliptin.
Triptorelin
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Triptorelin.
Valproate
The serum concentration of Valproic Acid can be decreased when it is combined with Linagliptin.
Valproic Acid
The serum concentration of Valproic Acid can be decreased when it is combined with Linagliptin.
Vemurafenib
The serum concentration of Linagliptin can be increased when it is combined with Vemurafenib.
Verapamil
The serum concentration of Linagliptin can be decreased when it is combined with Verapamil.
Vinblastine
The serum concentration of Linagliptin can be decreased when it is combined with Vinblastine.
Vincristine
The serum concentration of Linagliptin can be decreased when it is combined with Vincristine.
Vorinostat
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Vorinostat.
Zidovudine
The serum concentration of Zidovudine can be decreased when it is combined with Linagliptin.
Ziprasidone
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Ziprasidone.
Zofenopril
The risk or severity of adverse effects can be increased when Linagliptin is combined with Zofenopril.
